NCT00099606 - Phase I (PH I) Mad Refractory Solid Tumor Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions

Neoplasms

Interventions

DRUG

Dasatinib

Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.

Trial Locations (3)

Unknown

Local Institution, Boston

Local Institution, Detroit

Local Institution, Glasgow